Evidence for Existence of Immunoglobulins that Block Ovarian Granulosa Cell Growth<i>in Vitro</i>. A Putative Role in Resistant Ovary Syndrome?*

Weissenbruch, Mirjam M. van; Hoek, Annemieke; Vliet-Bleeker, Ingrid Van; Schoemaker, J.; Drexhage, Hemmo A.

doi:10.1210/jcem-73-2-360

Cited by 64 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The apoptosis of GC causes ovarian atresia and might eventually leads to POF. Therefore, the GC dysfunction is a main pathological feature of POF (8–12). The GC is the cell of origin in the pathogenesis of GCT (6), which is a clinically and molecularly unique subtype of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease

Cheung

Chan³

et al. 2019

Front. Endocrinol.

101

View full text Add to dashboard Cite

The granulosa cell (GC) is a critical somatic component of the ovary. It is essential for follicle development by supporting the developing oocyte, proliferating and producing sex steroids and disparate growth factors. Knowledge of the GC's function in normal ovarian development and function, and reproductive disorders, such as polycystic ovary syndrome (PCOS) and premature ovarian failure (POF), is largely acquired through clinical studies and preclinical animal models. Recently, microRNAs have been recognized to play important regulatory roles in GC pathophysiology. Here, we examine the recent findings on the role of miRNAs in the GC, including four related signaling pathways (Transforming growth factor-β pathway, Follicle-stimulating hormones pathway, hormone-related miRNAs, Apoptosis-related pathways) and relevant diseases. Therefore, miRNAs appear to be important regulators of GC function in both physiological and pathological conditions. We suggest that targeting specific microRNAs is a potential therapeutic option for treating ovary-related diseases, such as PCOS, POF, and GCT.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease

Cheung

Chan³

et al. 2019

Front. Endocrinol.

101

View full text Add to dashboard Cite

show abstract

“…[ 29 ] Subsequent studies have provided further evidence supporting this hypothesis. [ 20 , 21 , 30 , 31 ] Additionally, mutations in the FSH receptor gene have also been implicated as a potential cause of ROS. [ 15 , 32 , 33 ]…”

Section: Discussionmentioning

confidence: 99%

Resistant ovary syndrome: Two case reports and a literature review of effective controlled ovarian stimulation in IVF

Zhao,

Zheng,

et al. 2024

Medicine

View full text Add to dashboard Cite

Introduction: Resistant ovary syndrome (ROS) represents a rare reproductive endocrine disorder that is predominantly associated with infertility, characterized by heightened endogenous gonadotropin levels in the presence of a normal ovarian reserve. Patients with ROS typically exhibit a poor response to exogenous gonadotropins during controlled ovarian stimulation (COS). Due to the absence of a universally accepted effective COS protocol, this study aims to contribute to the existing body of literature by detailing 2 successful pregnancies achieved through conventional in vitro fertilization (c-IVF) in patients with ROS, and through retrospective analysis, seeks to elucidate the factors contributing to the successful ovarian stimulation in these cases, with the ultimate goal of establishing clinical guidelines for ROS management. Patient Concerns: The central challenge addressed in this study pertains to the effective induction of oocyte maturation during c-IVF COS in ROS patients. Diagnosis: The study focuses on 2 infertile women diagnosed with ROS who sought to conceive via c-IVF. Interventions: The patients were subjected to a COS protocol involving pituitary downregulation followed by ovarian stimulation using recombinant follicle-stimulating hormone (r-FSH) and human menopausal gonadotropin (HMG), preceded by 3 cycles of hormone replacement therapy (HRT) pretreatment. Outcomes: The proposed protocol elicited a favorable ovarian response, culminating in the retrieval of numerous mature oocytes and the development of multiple viable embryos via c-IVF, ultimately leading to successful live births post-embryo transfer. Conclusions: Our study suggests that the outlined COS protocol may serve as a viable treatment option for ROS patients aspiring to conceive through c-IVF, thereby potentially expanding the therapeutic repertoire for this challenging condition.

show abstract

“…Autoimmune disorders associated with humoral and cellular immunity results in antibody creation or T-cell mediated injury of ovarian cells such as GCs, oocytes, and the zona pellucida. [ 26 27 28 29 ]…”

Section: Discussionmentioning

confidence: 99%

Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: Review of literature and a case report of world's first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year

et al. 2018

View full text Add to dashboard Cite

Stem cell (SC) therapy has come up enormously, particularly for indications where not much can be done medically or surgically to improve the condition. SCs are the foundation cells for every organ, tissue, and cell in the body, and it can either reproduce into a SC or differentiate into specialized types of cells. Premature ovarian insufficiency (POI) is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins, low anti-Mullerian hormone (AMH), and estradiol level. Autologous SCs were tried in POI to increase the follicular recruitment and avoiding the need for oocyte donation program. This review analyzes the causes, etiopathogenesis, and role of autologous bone marrow-derived SC therapy (ABMDSCT) in POI. It also highlights the recent studies and summarizes the current understanding and future directions for SCs in POI. Here, we also report the first successful birth of a baby from India, where autologous SC therapy in a 45-year-old perimenopausal single woman helped in procuring a pregnancy and delivery of a healthy 2.7 kg female baby through assisted reproduction. In the absence of SC therapy, accepting oocyte donor program or adoption would have been the only viable options for this patient for which she was not ready. This may be the world's first successful case of application of ABMDSCT in a 45-year-old female to give successful birth to a healthy baby.

show abstract

Evidence for Existence of Immunoglobulins that Block Ovarian Granulosa Cell Growthin Vitro. A Putative Role in Resistant Ovary Syndrome?*

Cited by 64 publications

References 26 publications

The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease

The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease

Resistant ovary syndrome: Two case reports and a literature review of effective controlled ovarian stimulation in IVF

Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: Review of literature and a case report of world's first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year

Contact Info

Product

Resources

About